Genasense
information and resources from the National Cancer Institute
Genasense
(Other name for: oblimersen)Genexol-PM
(Other name for: paclitaxel-loaded polymeric micelle)Genasense
(Other name for: oblimersen)
|
|
|
|
news articles
Relapsed Or Refractory Chronic Lymphocytic Leukemia - Genasense(R) ... Mar 2, 2006
Medical News Today (press release), Nasdaq: GNTA) announced that the US Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Genasense(R) (oblimersen sodium ...
Genta Incorporated Announces Fourth Quarter and Year End 2005 ... Mar 10, 2006
PR Newswire (press release), Key highlights for the year included: * Genta completed submission of its New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection plus ...
Genta Receives Designation as a Small/Medium Enterprise by the ... Mar 16, 2006
PR Newswire (press release), Genta's Marketing Authorization Application (MAA) for Genasense(R) (oblimersen), the company's lead anti-cancer drug, is currently undergoing scientific review ...
FDA to review Genta drug in leukemia indication Mar 2, 2006
Pharmaceutical Business Review By Staff Writer. The FDA has accepted Genta Incorporated's new drug application for Genasense to be used in the treatment of chronic lymphocytic leukemia. ...
Genta and Emisphere Technologies Enter into Exclusive Worldwide ... Mar 23, 2006
Yahoo! News (press release) Genasense® (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has submitted ...
Genta Posts Q4 Loss On Lower Revenues - Update Mar 10, 2006
Trading Markets, ...company said the fourth quarter loss was due to the termination of a collaborative agreement in May 2005 with sanofi-aventis to commercialize Genasense for the ...
Genta Incorporated to Present at Cowen & Co. 26th Annual ... Mar 7, 2006
PharmaLive.com (press release), Genasense® oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has submitted ...
Drug Developers Have Yet to Bring Apoptosis Drugs to the Market Mar 23, 2006
Genetic Engineering News, The antisense drug nearest to market is oblimersen (Genta's Genasense), a first-generation drug being submitted for approval in the United States and Europe. ...
Genta study sees Genasense combo benefit Dec 12, 2005
BusinessWeek ...said Monday that preliminary clinical results from two studies show its cancer treatment Genasense significantly improved treatment responses in leukemia ...
Pilot Clinical Study of Genasense(R) Plus Rituxan(R) and ... Dec 12, 2005
PR Newswire (press release), Nasdaq: GNTA) announced the presentation of preliminary clinical results regarding the use of its lead anticancer compound, Genasense(R) (oblimersen sodium ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PR Newswire (press release), 6 /PRNewswire-FirstCall/- Genta Incorporated (Nasdaq: GNTA) announced that its lead anticancer drug Genasense(R) (oblimersen sodium) injection, and the central ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PharmaLive.com (press release), BERKELEY HEIGHTS, NJ, December 6, 2005 – Genta Incorporated (NASDAQ: GNTA) announced that its lead anticancer drug Genasense® (oblimersen sodium) injection ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PharmaLive.com (press release), BERKELEY HEIGHTS, NJ, December 06, 2005 /PRNewswire-FirstCall/- Genta Incorporated announced that its lead anticancer drug Genasense(R) (oblimersen sodium ...
(PRN) - UCC Capital's 2005 M&A Advisory & Financing Wins for ... Dec 6, 2005
Bolsamania.com, ...[+]. (PRN) - Annual Meeting of the American Society of Hematology Highlights Clinical Data with Genasense(R) and the Importance of its Target in Cancer ... [+. ...
Drug stocks slide, ID Biomedical halted Dec 6, 2005
Investor's Business Daily (subscription) The biotech group said it will be presenting data for its oncology drug Genasense for the treatment of lymphoma and leukemia during the annual meeting of the ...
|
|
